THE AMERICAN ASSOCIATION FOR CANCER RESEARCH announced 11 fellows of the AACR Academy.
JONATHAN JAROW was named acting director of the Office of Medical Policy in the FDA Center for Drug Evaluation and Research.
KAREN KNUDSEN was named interim director of the Sidney Kimmel Cancer Center and interim chair of the Department of Cancer Biology at Thomas Jefferson University.
The U.K. National Health Service established an access program for the Oncotype DX test, developed by Genomic Health Inc., for breast cancer patients, effective April 1.
FDA granted an Orphan Drug Designation to Reolysin for the treatment of pancreatic cancer.
FDA granted an Orphan Drug Designation to antinuclear antibody conjugated liposomal doxorubicin, developed by NanoSmart Pharmaceuticals Inc., for the treatment of Ewing's sarcoma, a rare cancer that develops in or around children's bones.
FDA granted an Orphan Drug Designation to Saposin C, the active ingredient in drug BXQ-350, for the potential treatment of glioblastoma multiforme.
FDA expanded the existing indication for Revlimid (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma.
THE MULTIPLE MYELOMA RESEARCH FOUNDATION and Inflection Biosciences announced a collaboration to test IBL-202, a dual-kinase inhibitor, in the treatment of myeloma.
The European Commission approved a variation to the terms of the marketing authorization of Velcade (bortezomib), in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for blood stem-cell transplantation.
